Ketanserin

A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.

Also Known As:

Networked: 756 relevant articles (67 outcomes, 125 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hong, Yanguo: 7 articles (10/2015 - 05/2006)
2.	Su, Ding-Feng: 5 articles (12/2013 - 07/2003)
3.	Vulto, Arnold G: 3 articles (06/2015 - 10/2005)
4.	Hanff, Lidwien M: 3 articles (06/2015 - 10/2005)
5.	Dean, Brian: 3 articles (06/2014 - 12/2004)
6.	Scarr, Elizabeth: 3 articles (06/2014 - 12/2004)
7.	Wang, Dongmei: 3 articles (12/2013 - 02/2010)
8.	Cai, Guo-Jun: 3 articles (12/2013 - 11/2010)
9.	Song, Shu-Wei: 3 articles (11/2011 - 01/2010)
10.	Duley, L: 3 articles (01/2006 - 01/2000)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1990 - "A number of symptoms related to peripheral circulatory disturbances, or possibly to hypertension itself, markedly improved during oral treatment with ketanserin." 10/01/1990 - "Our results indicate that monotherapy with ketanserin is effective in treating mild to moderate hypertension in both lean and obese hypertensives and does not interfere with left ventricular performance. " 05/01/1990 - "In conclusion, ketanserin was effective in the treatment of mild hypertension in patients with type 2 diabetes. " 03/01/1990 - "It is concluded that monotherapy with ketanserin is effective in treating mild to moderate hypertension in both lean and obese hypertensive patients, without interfering with left ventricular performance." 10/01/1989 - "Our results indicated that monotherapy with ketanserin is effective in treating mild to moderate hypertension both in lean and in obese hypertensives and did not interfere with left ventricular performance. "
2.	Pre-Eclampsia (Preeclampsia) 04/01/1996 - "Ketanserin, a 5-HT(2) receptor blocker, has been used successfully to treat preeclampsia. " 09/01/2006 - "Insufficient efficacy of intravenous ketanserin in severe early-onset pre-eclampsia." 08/01/2004 - "The aim of this prospective, observational study was to assess transplacental transmission of ketanserin, an antihypertensive drug used in pre-eclampsia, and to determine disposition and effects in the neonate after maternal ketanserin use. " 09/01/2000 - "Several studies confirmed that intravenous ketanserin decreases blood pressure significantly in patients with severe preeclampsia. " 10/01/2005 - "Ketanserin is an antihypertensive drug that is increasingly being used parenterally in the treatment of pre-eclampsia. "
3.	Ulcer 03/01/2006 - "Topical 2% ketanserin ointment, a 5HT2-serotoninergic blocking agent, has been reported to improve healing of decubitus, venous, diabetic and ischaemic ulcers. " 04/01/1990 - "Only one out of nine patients (11%) with a toe pressure below 30 mmHg in the placebo group healed or improved their ulcers compared to nine out of 16 (56%) in the ketanserin group. " 04/01/2001 - "At the end of the study, when ulcer sizes in the two groups were compared, the group treated with topical ketanserin showed superior results (p < 0.001 using Kolmogorov-Smirnov's test). " 01/01/1997 - "Thus, average daily reduction in ulcer area was 4.5 mm2/day for ketanserin vs. 2.88 mm2/day for placebo. " 01/01/1997 - "Average percent reduction in ulcer area at 12 weeks was 87% for ketanserin vs. 63% for placebo (p < 0.001). "
4.	Tachycardia (Tachyarrhythmias) 04/01/1986 - "The study showed that both agents were equally effective in decreasing the raised systolic blood pressure, but that ketanserin was more advantageous with respect to the absence of reflex tachycardia and the unchanged shunt fraction." 03/01/2002 - "The receptor mediating tachycardia directly has been classified as an 'atypical' 5-HT(2) receptor since it was 'weakly' blocked by ketanserin. " 08/01/1994 - "If administered during or after cardiac surgery, ketanserin lowers systemic and pulmonary blood pressure, and improves peripheral and pulmonary perfusion without causing reflex tachycardia or an increase in pulmonary shunt fraction." 04/01/1992 - "It also reduces systemic vascular resistance without reflex tachycardia and this is a favorable effect of ketanserin." 04/01/1989 - "Ketanserin had no presynaptic effects on the sympathetic nerve terminals as evidenced by the lack of effect on the tachycardia induced by electrical stimulation of the sympathetic outflow in pithed rats. "
5.	Hyperalgesia 10/25/2015 - "Ketanserin given once per day at a dose of 80 µg abolished heat hyperalgesia and also attenuated mechanical allodynia on the third day. " 10/25/2015 - "The results showed that ketanserin administered in the inflamed site inhibited thermal hyperalgesia in a dose-dependent manner (20, 40 and 80 µg) induced by the intraplantar injection of CFA. " 02/10/2010 - "Injection of ketanserin (0.3mg/kg) also suppressed tactile allodynia. " 02/10/2010 - "Daily injection of ketanserin inhibited the thermal hyperalgesia in a dose dependent manner (0.1 and 0.3mg/kg, s.c.). " 09/01/2011 - "In contrast to spinal delivery, systemic and local peripheral injections of ketanserin or pruvanserin alleviated tactile allodynia in diabetic rats. "

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Propranolol (Inderal)
3.	Serotonin Receptors
4.	Ritanserin
5.	Aspirin (Acetylsalicylic Acid)
6.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
7.	Prazosin (Minipress)
8.	Metoprolol (Lopressor)
9.	Dihydralazine
10.	Antipsychotic Agents (Antipsychotics)

Related Therapies and Procedures

1.	Amputation
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Cardiopulmonary Bypass (Heart-Lung Bypass)
4.	Drug Therapy (Chemotherapy)
5.	Resuscitation